Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01076049
Other study ID # 108527
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 2010
Est. completion date December 2011

Study information

Verified date August 2021
Source Irrimax Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine whether Irrisept can effectively prevent the progression of skin and soft tissue infections (SSTIs) as compared to treatment by the current Standard of Care.


Description:

After being informed about the trial and potential risks, subjects completed an informed consent form prior to participation. After eligibility criteria was verified, an initial wound assessment examination was performed. Subjects were then randomized to the Irrisept or Standard of Care treatment group. Forty-eight hours later, wound progression and signs of infection were assessed.


Recruitment information / eligibility

Status Terminated
Enrollment 114
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age 18 to 80 2. Skin and soft tissue infections (SSTIs), in the form of an abscess, which will require incision and drainage. 3. Patient able to provide an informed consent. 4. Patient volunteers to participate. Exclusion Criteria: 1. Wound was caused by human or animal bite. 2. Wound is a blunt crush injury or has tendon, bone, or joint involvement. 3. Diabetic foot infection. 4. Anticipated incision size less than 5mm. 5. Abscess extends to the muscle layer. 6. Admission to hospital for any reason, including IV antibiotics. 7. Clinical signs of systemic infection on initial patient encounter. 8. Prior history of allergy or hypersensitivity to CHG. 9. Neutropenic (known ANC<500/mm3), HIV (known CD4<50), or other severely immunocompromised state (e.g., receiving chemotherapy). 10. Patient is diagnosed with systemic lupus erythematosus or other immunological disease. 11. Currently in police custody. 12. Patient withdraws from participation. 13. Patient unable or unwilling to give informed consent.

Study Design


Intervention

Device:
Standard of Care (SoC)
The preferred irrigation solution and method was chosen by the site's emergency department physician(s) and could vary between subjects. The type of SoC was recorded in the source document and the same solution and irrigation method were used during the initial treatment and 48-hour follow-up visits.
Irrisept Delivery System
Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. Irrisept was recorded in the source document and used during the initial treatment and 48-hour follow-up visits.

Locations

Country Name City State
United States Tampa General Hospital - University of South Florida Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Irrimax Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound State at 48-Hour Follow-up Visit The primary endpoint was overall wound progression and signs of infection 48 hours post-treatment. This was measured via a blinded investigator's discretion and recorded as 'improved', 'no change', 'progression of signs or symptoms of infection', or 'immediate treatment required' if an infection had progressed to a certain extent. 48 hours
Secondary Clinical Performance of Irrisept to the Current SoC The study tracked any instance of a subject's conditions worsening compared to their baseline measurements. This included a worsening in the size (length and width) and clinical signs (erythema, area, induration, tenderness, warm, pain, cellulitis and other) of the infection.
While the protocol states the overall prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) colonization is the secondary objective, this information was not collected by the site. Therefore, worsening of clinical outcomes is considered the secondary objective.
48 hours
See also
  Status Clinical Trial Phase
Terminated NCT03127371 - Adjunctive Nitrous Oxide During ED Incision and Drainage of Abscess N/A
Completed NCT02240498 - Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities Phase 1
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT00402727 - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection Phase 3
Completed NCT00352612 - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Phase 4
Completed NCT00137085 - Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation N/A
Completed NCT02714023 - Water And Saline Head-to-head In The Blinded Evaluation Study Trial N/A
Completed NCT02264392 - US Guided Versus BlindI&D for Treatment of Soft Tissue Abscesses in the ED N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Withdrawn NCT04241471 - Incision and Loop Drainage Utilizing a Novel Technique for Management of Cutaneous Abscess in an Adult Population N/A
Recruiting NCT06284473 - Ketamine as a Supplement to Local Anesthesia for Minor Procedures Phase 4
Completed NCT01235546 - Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection N/A
Withdrawn NCT00900510 - Antibiotic Therapy After Incision and Drainage for Abscess N/A
Not yet recruiting NCT03917134 - Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy N/A
Withdrawn NCT02703233 - Effectiveness of Nitrous Oxide in the ED Phase 4
Completed NCT01557426 - Soft Tissue Ultrasound of Infections Phase 1
Completed NCT01339091 - Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT01784458 - Clinical Significance of Intra-abdominal Hypertension in Surgical Patients With Severe Sepsis N/A
Terminated NCT00867789 - Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department N/A
Completed NCT00984022 - Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage Phase 2